Illustrative image – not actual.
The government has approved three foreign direct investment (FDI) proposals, all related to the pharmaceutical sector, worth Rs 60.73 crore.
The highest FDI proposal of the three pharmaceutical companies which got the nod was from Advanced Enzyme Technologies. The company sought approval for investment proposed to be made by FIIs / NRIs / FPIs / QFIs / AIF / FVCIs pursuant to fresh issue of, and offer for sale of 44,73,470 equity shares by certain NRIs and resident shareholders worth Rs 60 crore.
The other two companies whose proposals were approved include Wockhardt, which asked for post facto approval for issuance of ESOPs to its two NRI employees, and Aurobindo Pharma which sought clarification and approval regarding grant of ESOPs to a non-resident employee.
Axis Bank’s FDI proposal worth Rs 12,973.14 crore to increase foreign investment by FIIs / NRIs/ FPIs / ADRs / GDRs from 62 percent to 74 percent has been referred to the Cabinet Committee on Economic Affairs (CCEA). This is in line with the government's decision to refer all FDI proposals above Rs 5,000 crore to the CCEA.
Eight proposals including those from Macmillan Publishers, UK; JCB International; Janalakshmi Financial Services; and Fans Asia have been deferred, while a proposal by Rafique Dawood in the manufacturing sector has been rejected.
The decisions have been taken based on recommendations made by the FIPB at its meeting of 29 April, 2016.
